A retrospective analysis of long term outcomes in patients undergoing hepatic resection for large (&gt;5 cm) hepatocellular carcinoma

Zhao, Hua-Lu; Wu, Ruolin; Liu, Fubao; Zhao, Yupei; Wang, Guobin; Zhang, Zhigong; Huang, Fan; Xie, Kun; Geng, Xiaoping

doi:10.1016/j.hpb.2016.08.005

Cited by 23 publications

(19 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3,4 Previous studies have reported improved outcomes using radiotherapy+TACE combination therapy compared with TACE or radiotherapy alone. [5][6][7] However, there are no comparative studies on the efficacy of HR and CK-SBRT+TACE in the treatment of large HCC. Therefore, we conducted a retrospective analysis to compare long-term survival following CK-SBRT+TACE versus HR for patients with large HCCs (5-10 cm) that were treated in our medical center.…”

Section: Introductionmentioning

confidence: 99%

Hepatic Resection Versus Stereotactic Body Radiation Therapy Plus Transhepatic Arterial Chemoembolization for Large Hepatocellular Carcinoma: A Propensity Score Analysis

Sun¹,

Li²,

Wang³

et al. 2021

Journal of Clinical and Translational Hepatology

View full text Add to dashboard Cite

Background and Aims:There are no comparative studies on the efficacy of hepatic resection (HR) and CyberKnife stereotactic body radiation therapy (CK-SBRT) plus transhepatic arterial chemotherapy embolization (TACE) in the treatment of large hepatocellular carcinoma (HCC). Therefore, this study aimed to compare the efficacy of HR and CK-SBRT+TACE in large HCC. Methods: A total of one hundred and sixteen patients were selected from November 2011 to December 2016. Among them, 50 were allocated to the CK-SBRT+TACE group and 66 were allocated to the HR group. The Kaplan-Meier method was applied to calculate overall survival (OS) and progression-free survival (PFS) rates. Propensity score matching was performed to control for baseline differences between the groups. Results: Thirtysix paired patients were selected from the CK-SBRT+TACE and HR groups. After propensity score matching, the 1-, 2-and 3-year OS rates were 83.3%, 77.8% and 66.7% in the HR group and 80.6%, 72.2% and 52.8% in the CK-SBRT+TACE group, respectively. The 1-, 2-and 3-year PFS rates were 71.6%, 57.3% and 42.3% in the HR group and 66.1%, 45.8% and 39.3% in the CK-SBRT+TACE group, respectively (OS: p=0.143; PFS: p=0.445). Both a high platelet count and low alpha-fetoprotein value were revealed as influencing factors in improving OS and PFS. Conclusions: CK-SBRT+TACE brought local effects that were similar to those of HR in HCC patients with a large and single lesion.Moreover, the liver injury occurrence rate was acceptable in both groups.

show abstract

Section: Introductionmentioning

confidence: 99%

Hepatic Resection Versus Stereotactic Body Radiation Therapy Plus Transhepatic Arterial Chemoembolization for Large Hepatocellular Carcinoma: A Propensity Score Analysis

Sun¹,

Li²,

Wang³

et al. 2021

Journal of Clinical and Translational Hepatology

View full text Add to dashboard Cite

show abstract

“…Several retrospective studies compared HR and TACE in solitary HCC >5 cm, and reported 5-year OS of 43-65% and 17.5-49.6% for HR and TACE respectively [39][40][41] . Two studies regarding HR in HCC >5 cm by Zhao et al 42 and Hwang et al 43 reported OS of 75%, 59% and 44% and 78.4%, 58.8% and 49.3% at 1-, 3-and 5-years, respectively. For HCC (>10 cm), Zhou et al 44 showed OS of 60.7%, 34% and 28.6% at 1-, 3-and 5-years respectively.…”

Section: Discussionmentioning

confidence: 98%

Safety and efficacy of stereotactic radiofrequency ablation for very large (≥8 cm) primary and metastatic liver tumors

Schullian

Johnston

Putzer

et al. 2020

Sci Rep

View full text Add to dashboard Cite

To assess the safety and clinical outcomes of multi-probe stereotactic radiofrequency ablation (SRFA) for very large (≥8 cm) primary and metastatic liver tumors with curative treatment intent. A retrospective, single center study carried out between 01.2005 and 06.2018. 34 consecutive patients had a total of 41 primary and metastatic liver tumors with a median size of 9.0 cm (8.0-18.0 cm) at initial SRFA. Patients were treated under CT guidance using a 3D navigation system. Endpoints consisted of (i) technical efficacy; primary-requiring one treatment, and secondary-requiring two treatments (ii) complication and mortality rates (iii) local and distant recurrence (LR), (iv) disease free survival (DFS), (v) overall survival (OS). 33/41 tumors were successfully ablated at initial SRFA (80.5% primary technical efficacy rate (PTE)). Four tumors required repeat ablation, resulting in a secondary technical efficacy (STE) rate of 90.2%. Local tumor recurrence (LR) developed in 4 of 41 tumors (9.8%). The 30day perioperative mortality was 2.3% (1/ 44 ablations). The total major complication rate was 20.5% (9 of 44 ablations). Three of nine (33.3%) major complications, such as pleural effusion, pneumothoraces or perihepatic hemorrhages were relatively easy to treat. The overall survival (OS) rates at 1-, 3-, and 5-years from the date of the first SRFA were 87.1%, 71.8%, and 62.8% for patients with hepatocellular carcinoma (HCC) and 87.5%, 70.0% and 70.0% for patients with intrahepatic cholangiocarcinoma (ICC) respectively. Patients with metastatic disease had OS rates of 77.8% and 22.2% at 1-and 3-years. The clinical results of SRFA in this study are encouraging and warrant a prospective multicenter study. SRFA may become one of the best therapeutic choices for a growing number of patients with primary and metastatic liver cancer.

show abstract

“…The mean age of the patients is 55 yr old. Clinically, the tumor with the maximum diameter larger than 5 cm is the large tumor and that less than 3 cm is the small tumor. Therefore, the maximum diameters of the tumors in the dataset are divided into three categories.…”

Section: Methodsmentioning

confidence: 99%

Local incompressible registration for liver ablation surgery assessment

Liu

et al. 2017

Medical Physics

View full text Add to dashboard Cite

show abstract

A retrospective analysis of long term outcomes in patients undergoing hepatic resection for large (>5 cm) hepatocellular carcinoma

Cited by 23 publications

References 24 publications

Hepatic Resection Versus Stereotactic Body Radiation Therapy Plus Transhepatic Arterial Chemoembolization for Large Hepatocellular Carcinoma: A Propensity Score Analysis

Hepatic Resection Versus Stereotactic Body Radiation Therapy Plus Transhepatic Arterial Chemoembolization for Large Hepatocellular Carcinoma: A Propensity Score Analysis

Safety and efficacy of stereotactic radiofrequency ablation for very large (≥8 cm) primary and metastatic liver tumors

Local incompressible registration for liver ablation surgery assessment

Contact Info

Product

Resources

About